Figure F-165 is titled “Rate of drowsiness for SSRIs compared with placebo.” The figure displays a forest plot reporting the risk difference of drowsiness for SSRIs compared with placebo stratified by paroxetine compared with placebo and sertraline compared with placebo. The forest plot depicts that a lower rate of drowsiness occurred among patients treated with paroxetine (1 trial, risk difference −0.15, 95% CI −0.51 to 0.21) compared with placebo and that a higher rate of drowsiness occurred in patients treated with sertraline (4 trials, risk difference 0.05, 95% CI −0.00 to 0.11, I2=0.0%) compared with placebo. Overall there was a 5% higher rate of drowsiness related to SSRIs than placebo (risk difference 0.05, 95% CI −0.01 to 0.11, I2=0.0%).

Figure F-165Rate of drowsiness for SSRIs compared with placebo

Timing of outcome assessment: 10 weeks (Simon, 2008; Panahi, 2011; Zohar, 2002), 12 weeks (Brady, 2000; Davidson, 2001).

From: Appendix F, Meta-Analysis

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.